Alzheimer's risk could rise with specific sleep pattern, experts warn
The research from China, published in the journal Alzheimer's & Dementia by the Alzheimer's Association, analyzed the sleep cycles of 128 adults in varying states of cognition.
Advertisement
The study found that the highest occurrence of REM latency — which is when it takes longer for someone to reach the first REM period after drifting off to sleep — was associated with the highest risk of Alzheimer's.
The researchers concluded that prolonged REM latency may serve as a 'novel marker of risk factor' for Alzheimer's disease and related dementias.
Dr. Wendy Troxel, senior behavioral scientist at the RAND Corporation in California, said this study adds to 'growing evidence' that specific sleep features, like prolonged REM sleep, are linked to Alzheimer's biomarkers.
'REM sleep is the stage of sleep when dreams mostly occur, and is critically important for memory consolidation and emotional processing,' Utah-based Troxel, who is also author of 'Sharing the Covers: Every Couple's Guide to Better Sleep,' told Fox News Digital.
Advertisement
This new research aligns with findings from Troxel's own lab, which have shown that other signs of poor sleep health — like shorter duration and poor quality — are associated with worse cognitive function.
'Sleep disruptions may contribute to the buildup of amyloid and tau proteins, key features of Alzheimer's pathology,' the sleep expert said.
5 A new study has found a link between rapid eye movement (REM) sleep and Alzheimer's disease.
amenic181 – stock.adobe.com
'But it's also important to note that the Alzheimer's disease process itself can disrupt sleep, suggesting a bidirectional association between sleep problems and cognitive decline.'
Advertisement
Dr. Giulio Taglialatela, vice president and research institute director of the Brain Health Institute at the University of Texas Medical Branch, reacted to these findings in a separate interview with Fox News Digital.
Taglialatela said it's been 'long understood' that getting a good night's sleep is associated with a lower risk of developing dementia.
'Our brains use sleep to clear out toxic proteins, like those associated with Alzheimer's, and these results show that the cleaning mechanism is less effective when it takes someone longer to enter the REM cycle,' he noted.
5 The study found that the highest occurrence of REM latency was associated with the highest risk of Alzheimer's.
Rawpixel.com – stock.adobe.com
Advertisement
'Unfortunately, there is nothing an individual can do to control how long it takes to enter REM sleep,' the expert.'
However, the expert said, the findings provide a 'promising avenue' for predicting the likelihood of someone eventually developing dementia.
'Early intervention in Alzheimer's is essential for delaying its progression, and measuring REM sleep could be a marker to indicate who may be a candidate for treatment even before they start to show impaired cognitive function,' Taglialatela said.
Potential limitations
5 'Our brains use sleep to clear out toxic proteins, like those associated with Alzheimer's, and these results show that the cleaning mechanism is less effective when it takes someone longer to enter the REM cycle,' Dr. Giulio Taglialatela noted.
sudok1 – stock.adobe.com
The study did have some limitations, the researchers acknowledged – primarily that it was cross-sectional, 'and thus the direction of the association cannot be determined.'
The sample size was also relatively small, and the researchers only focused on one specific type of tau protein.
There is also the possibility that monitoring sleep in a clinical setting may introduce 'environmental disturbances,' impacting sleep measurement accuracy, the researchers noted. 'Future studies will benefit from research in real-world home settings,' they wrote.
Tips for sleep improvements
5 The study did have some limitations, the researchers acknowledged – primarily that it was cross-sectional, 'and thus the direction of the association cannot be determined.'
LIGHTFIELD STUDIOS – stock.adobe.com
Advertisement
While these findings are important, Troxel said, she encourages individuals to not allow the information to be 'another source of worry that keeps you awake at night.'
'Avoid the tendency to become overly fixated on metrics like REM sleep percentage or latency from consumer sleep trackers, as they have limited accuracy in determining sleep architecture,' she cautioned. 'Obsessing on such data can increase anxiety, which is a powerful sleep disruptor.'
Every morning, the NY POSTcast offers a deep dive into the headlines with the Post's signature mix of politics, business, pop culture, true crime and everything in between. Subscribe here!
The best approach is to focus on the foundations of good sleep health, the expert said.
Advertisement
Adults should strive for seven to nine hours of shuteye and should maintain consistent sleep and wake times, according to Troxel.
5 Adults should strive for seven to nine hours of shuteye and should maintain consistent sleep and wake times, according to experts.
Satawat – stock.adobe.com
'Minimize common disruptors such as excessive caffeine and alcohol, which are known to fragment REM sleep, [as well as] screen use before bedtime,' she added.
Advertisement
'Focusing on these core sleep habits is the most effective and evidence-based way to support the brain and overall health.'
Taglialatela also encourages individuals to focus on creating an 'ideal sleep environment' while maintaining 'good bedtime habits' to reduce the risk of developing Alzheimer's.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
5 hours ago
- Time Business News
Artificial Intelligence Transforming Healthcare and Improving Lives
Artificial intelligence (AI) has emerged as a groundbreaking force reshaping the healthcare landscape. Its rapid advancement over the past decade has led to improved diagnostics, personalized treatment, efficient management of health services, and the democratization of medical knowledge and care. In this comprehensive analysis, we will explore how AI is elevating health outcomes, the mechanisms behind these advancements, its impact on patients and practitioners, challenges faced, and the future outlook of AI-driven healthcare. AI refers to computer systems capable of performing tasks that typically require human intelligence, such as learning, reasoning, pattern recognition, and decision-making. Within healthcare, AI draws upon vast medical datasets—ranging from electronic health records and genetic data to real-time wearable device streams—and applies sophisticated algorithms to uncover patterns, predict outcomes, and recommend optimal interventions. The goal is not to replace clinicians and caregivers but to amplify their abilities, reduce diagnostic errors, and enable personalized, efficient, and timely care. One of the most transformative applications of AI in healthcare is in disease diagnosis, particularly using medical imaging. AI-powered tools can analyze X-rays, CT scans, MRIs, and retinal scans at incredible speeds and with accuracy levels that often match or surpass human experts. Advanced algorithms are trained on millions of medical images, allowing them to detect subtle changes in tissue and anatomical structures that indicate diseases such as: Cancer (breast, lung, skin, and prostate): AI can spot early tumor growths that radiologists might miss, aiding in earlier detection and better patient outcomes. (breast, lung, skin, and prostate): AI can spot early tumor growths that radiologists might miss, aiding in earlier detection and better patient outcomes. Eye diseases : Diabetic retinopathy and age-related macular degeneration can be detected using AI analysis of retinal imagery, helping prevent blindness. : Diabetic retinopathy and age-related macular degeneration can be detected using AI analysis of retinal imagery, helping prevent blindness. Neurological disorders: AI models detect anomalies in brain scans indicating conditions like epilepsy, stroke, and Alzheimer's far more quickly than standard methods. Medical errors are a leading cause of preventable harm. By double-checking, highlighting anomalies, and flagging uncertain cases for further review, AI minimizes oversight. For example, a study showed that AI could detect breast cancer on mammograms with higher sensitivity and specificity than radiologists. No two people are biologically identical. The same disease may progress differently among patients due to genetic, lifestyle, and environmental variations. AI plays a vital role in making precision medicine a reality—treatments are customized based on individual molecular profiles. By analyzing genomic data, AI predicts how a patient will respond to specific drugs, identifies genetic risks, and helps design gene therapies. Continuous glucose monitoring systems empowered by AI adjust diabetes management in real time, analyzing dietary intake, exercise, and blood sugar trends to optimize insulin delivery. Similarly, wearable devices combined with AI alert heart failure patients before their condition worsens, enabling early intervention and reduction in hospitalizations. Conventional drug discovery is costly and time-consuming. AI revolutionizes this process by: Screening millions of compounds for drug candidates at unprecedented speeds. Predicting drug efficacy, optimal dosages, and potential side effects. Personalizing drug combinations for individuals based on genetic makeup and disease behavior. This accelerates the arrival of novel treatments and reduces costs, making medicine more accessible. AI helps predict who is at risk of developing certain conditions (like diabetes, cardiovascular disease, or sepsis) by analyzing medical records, social determinants, and lifestyle data. Early identification allows for proactive interventions—ranging from lifestyle modifications to preemptive medication—which can delay or even prevent disease onset. Hospital readmission within 30 days is costly for both patients and systems. Several health systems use AI algorithms to flag patients at high risk of readmission so care teams can intervene with additional monitoring, support, home visits, or telemedicine follow-ups. AI can detect patterns in public health data, travel patterns, social media signals, and genomic sequencing of pathogens. This helps forecast infectious disease outbreaks (such as influenza, COVID-19, or Ebola), allowing leaders to pre-position resources and enforce public health policies quickly. AI-driven chatbots and voice assistants operate around the clock, answering patient questions, managing appointments, providing medication reminders, and offering first-line triage advice. For individuals with chronic diseases, these tools check on symptoms daily, record vitals, and escalate issues to care teams when necessary. Digital therapeutics use AI-powered mobile apps to deliver behavioral interventions, manage pain, encourage activity, and support mental health. For example, apps can coach users through exercises to relieve chronic pain, offer personalized cognitive behavioral therapy for anxiety and depression, or gamify medication adherence for children. Wearables and home-based sensors collect data on heart rate, blood pressure, oxygen saturation, movement, and even sleep patterns. AI interprets this data, highlighting trends, and alerting caregivers early when intervention is needed, thus enabling proactive care outside the traditional clinic setting. Healthcare systems face immense pressure to improve efficiency while maintaining quality. AI optimizes scheduling, resource allocation, and administrative workflows: Triage : AI-powered systems assist paramedics in determining the severity of ambulance cases and the most appropriate hospital destination, saving time and lives. : AI-powered systems assist paramedics in determining the severity of ambulance cases and the most appropriate hospital destination, saving time and lives. Clinical documentation : Automated transcription and smart note-taking free up doctors from paperwork, allowing more focus on patient care. : Automated transcription and smart note-taking free up doctors from paperwork, allowing more focus on patient care. Billing and claims: AI reviews insurance claims, identifying fraud, reducing errors, and speeding up reimbursement. Clinical trials are expensive and often delayed due to challenges in site selection and patient recruitment. AI helps to: Identify optimal trial sites based on real-world data. Match eligible and diverse participants, ensuring broader and more relevant trial results. Predict and mitigate obstacles—such as withdrawals or protocol violations—by adapting recruitment and retention strategies in real time. By shortening time-to-diagnosis, minimizing preventable admissions, and improving treatment efficacy, AI helps control rising healthcare expenditures. It also contributes to value-based care models by improving outcomes while using fewer resources. AI-powered systems synthesize large volumes of medical literature, guidelines, and individual patient data to provide clinicians with evidence-based recommendations—helping them select the most effective therapies, avoid harmful drug interactions, and keep up with the ever-growing body of medical knowledge. Virtual patients and intelligent simulation platforms powered by AI enhance medical training, allowing clinicians and students to practice complex scenarios and receive tailored feedback. AI also helps identify gaps in knowledge, guiding continuous professional development. A significant proportion of the world's population lacks ready access to quality healthcare, often due to provider shortages, geographic barriers, or cost. AI is helping bridge this gap: Remote diagnostics : AI tools enable health workers in low-resource settings to screen for diseases with smartphone-based imaging and cloud analytics. : AI tools enable health workers in low-resource settings to screen for diseases with smartphone-based imaging and cloud analytics. Automated translation : Multilingual AI models facilitate communication between patients and providers, breaking down language barriers. : Multilingual AI models facilitate communication between patients and providers, breaking down language barriers. Telemedicine platforms: AI-driven services connect patients anywhere with specialists, extending high-level care to underserved areas. The transformative promise of AI comes with substantial challenges: AI depends on sensitive medical data. Ensuring this data is secure, anonymized, and used ethically is paramount. Health organizations must comply with strict privacy regulations and remain vigilant to cyber threats. AI models can perpetuate existing health disparities if trained on unrepresentative data. Biases in algorithms may lead to worse outcomes for minority or marginalized populations. Ongoing efforts focus on transparent data collection, bias detection, and inclusive model development. Clinicians might distrust or resist AI recommendations, especially if the system's reasoning is opaque ('black box' problem). To foster adoption, AI outputs must be explainable and integrated into clinical workflows. AI-enabled devices and software require rigorous regulatory approval to ensure effectiveness and safety. Standards are still evolving, and regulatory bodies worldwide are updating frameworks to keep pace with AI innovation. Google Health's AI model trained on mammograms achieved higher accuracy than radiologists in identifying breast tumors, reducing both false negatives and false positives. This has led to earlier interventions and potentially saved lives. In India, AI-based retinal screening allows technicians to identify diabetic retinopathy in local clinics, referring only urgent cases to distant specialists. This has improved outcomes for thousands who previously lacked access to eye care. AI-powered robots and digital companions provide reminders, monitor mood and safety, and offer social interaction for older adults. These systems, already in use in parts of Europe and Asia, reduce loneliness and delay the need for institutional care. During the pandemic, AI helped accelerate vaccine development, optimize supply chains for personal protective equipment, track outbreaks, and inform public health decision-making by modeling possible scenarios. The journey of AI in healthcare is just beginning. In the coming years, we can expect: Further integration of multi-modal data (genomic, clinical, imaging, behavioral, and social determinants) to enhance predictive power and personalize interventions. Growing democratization of diagnostic and monitoring tools via smartphones and low-cost devices. Real-time adaptive clinical guidelines—algorithms that continuously learn from new data, clinical outcomes, and real-world evidence. Expansion of AI's reach into mental health, voice analysis for neurological and psychiatric disorders, and advanced prosthetics. Closer collaboration between AI developers, clinicians, regulatory bodies, and patients to ensure AI tools are transparent, ethical, and trusted. Artificial intelligence is not a panacea, but it is a catalyst—empowering clinicians, engaging patients, and optimizing the use of resources with the ultimate goal of better health for all. Responsible adoption and ongoing vigilance regarding ethics, equity, and privacy are essential to harness the benefits and minimize risks. As AI continues to evolve, its positive impact on the healthcare ecosystem will become ever more profound, bringing us closer to a future where health is more predictive, personalized, preventive, and accessible TIME BUSINESS NEWS
Business Journals
12 hours ago
- Business Journals
Building a greener, smarter future
San Leandro's Gate510 campus has quickly become a hub for companies shaping the future of multiple industries. Air Protein, Coreshell and Lyten are among the innovators leveraging the infrastructure and support for makers in San Leandro. Read on to discover how they're redefining what's possible. AIR PROTEIN NASA-inspired research drives sustainable food production A food production facility that once made such American breakfast innovations as Eggo Waffles and Pop-Tarts is aiming to change the way we eat once again, this time with a sustainable twist. Air Protein opened its first Air Protein Farm on San Leandro's Gate510 campus in 2023, where it does just what its name suggests: make high-quality protein out of particles in the air. Co-founders Lisa Dyson and John Reed were inspired by research from the early days of NASA, which explored ways astronauts could produce food on long space journeys. They built on that work, creating a method for growing protein in cultures, similar to the production of yogurt, cheese, and wine. The result is a neutral-tasting protein flour that can be turned into or used in any food. 'We and our investors believe we've cracked the code on making functional ingredients that have a great cost profile,' Dyson said. 'Many companies are also looking for ingredients that are resource-efficient, and that's what we do. We help CPG [Consumer Packaged Goods] companies make great products for consumers.' In choosing San Leandro, Air Protein put the company's headquarters in a location with a history of food manufacturing. Dyson said the Air Protein project team and the landlord worked closely with the City throughout the process to obtain the necessary permits for building out the facility. 'With this particular site and location, there is fermentation happening with other companies around us,' Dyson said. These include 21st Amendment Brewery and Drake's Brewing. 'That made this more appealing than some other options.' The San Leandro Air Protein Farm produces samples of its protein in large enough quantities for food product companies to use in their product development. Next up will be a larger commercial facility to support full-scale use of Air Protein in food for grocery shelves. 'That's the most exciting thing about 2025,' Dyson said. 'We're turning the science innovation that NASA started in the 1960s and 1970s, completing the mission and making it a reality.' LYTEN San Leandro lands new battery cell production facility Every once in a while, an opportunity comes along that is just too good to pass up. That's what happened to Lyten, a San Jose-based company specializing in supermaterial applications, which focuses on commercializing lithium-sulfur batteries as a high-performance, low-cost alternative to lithium-ion technology. The company was in the process of planning a gigafactory in Nevada and thinking about its next major production facility outside California when the perfect location popped up in San Leandro, said Chief Battery Technology Officer Celina Mikolajczak. A lithium-metal battery maker had closed, leaving behind a manufacturing space and equipment that was immediately of interest. Lyten snapped up the equipment and 119,000-square-foot lease at Gate510 that November. Mikolajczak expects to have a 100-megawatt-hour production line in San Leandro up and running in 2026. 'We were planning and tooling for a big factory, and then the opportunity to take over the lease in San Leandro occurred,' she said. 'We said, 'Wow, that's a big enough space. There's enough dry room capability there. There's enough power. We could get one high-volume production line running there and learn a hell of a lot and get a jump on being ready for a bigger factory.' Lyten's San Leandro site will deliver lithium-sulfur battery cells for multiple types of energy storage customers, including defense and drone applications. In doing so, the company will help U.S. manufacturers keep more of their supply chain close to home. 'With lithium-sulfur, we can develop the technology and commercialize it in the U.S. and be part of creating the next wave of manufacturing in this country,' Mikolajczak said. CORESHELL New battery anodes boost domestic supply chain Batteries have quickly become a crucial component in efforts to transition from fossil fuels to sustainable forms of energy. But the batteries most widely used in electric vehicles and other key applications today come with limitations. San Leandro-based Coreshell is one of the innovators working to change this. The company has developed a battery anode that uses 100% domestically sourced metallurgical silicon instead of graphite, allowing it to store significantly more energy without relying on a risky supply chain. 'We're replacing something that is produced only in China with silicon that is produced widely here in the United States and in Europe,' said Co-founder and CEO Jonathan Tan. 'It can be even more cost-effective.' Founded in 2017, Coreshell relocated its development work to the Gate510 campus in 2020 and opted to remain in the city when it was time to expand into the first stages of production in 2024. It moved across the street to another building on the Gate510 campus, where a team of approximately 50 people has a four megawatt-hour pilot production facility that produces its first battery cells ready for commercialization in electric vehicles. 'We're proposing a foundational change in battery chemistry by replacing graphite — one of the largest single materials in a battery — with silicon,' Tan said. 'It is imperative that we show the market how that will help people power their daily lives.' San Leandro was ideal because it offered a combination of the necessary infrastructure — including access to the heavy power Coreshell needs for manufacturing — and efficient permitting and other City support, Tan said. A San Leandro headquarters also gives Coreshell access to a strong talent pipeline from throughout the Bay Area's growing battery expertise. San Leandro Mayor Juan Gonzalez, and members of the City staff visited with Coreshell this spring. It was an opportunity for Tan and his team to share more about their work and talk about how the City can support the company's future growth. 'To have a receptive audience with the Mayor, the City Manager's office and others in San Leandro, it shows that they are invested in helping companies like Coreshell grow and be successful,' Tan said. 'We value that partnership and how they are actively working to find ways to support the success and growth of companies like ours.'
Business Wire
14 hours ago
- Business Wire
NJ Rallies Investment Power, Leveraging Capital from Garden State Venture Partners to Drive MedTech and Maternal Health Innovation
GLASSBORO, N.J.--(BUSINESS WIRE)--Two transformative healthcare announcements this week mark a new era for New Jersey's innovation economy—with Garden State Venture Partners (GSVP) emerging as a key catalyst behind both. These initiatives represent over $100 million in coordinated investment, a model of public-private partnership, and a strategic bet on New Jersey as the next national hub for health tech and equity-focused innovation. Share 1. MedTech Strategic Innovation Centers Backed by GSVP & NJEDA On July 21, NJEDA and Rowan University unveiled a major initiative to launch a Strategic Innovation Center, with locations in Camden and Mullica Hill, supporting early-stage medical technology companies with critical lab space, mentorship, and commercialization resources. GSVP, a New Jersey-based venture firm committed to fueling statewide innovation, is helping to make this possible through venture capital funding for early-stage medtech companies. Read release 2. A First-of-Its-Kind Maternal and Infant Health Innovation Center in Trenton Just one day later, Governor Murphy and First Lady Tammy Murphy broke ground on a Trenton-based center dedicated to maternal and infant health equity. The MedTech Strategic Innovation Center will also have a presence at the Maternal and Infant Health Innovation Center, which will focus on medical technologies that address racial disparities in care. Once again, GSVP will play a central role in helping bridge the gap between public health needs and private-sector innovation by accelerating promising, equity-driven health tech ventures. Read release Together, these initiatives represent over $100 million in coordinated investment, a model of public-private partnership, and a strategic bet on New Jersey as the next national hub for health tech and equity-focused innovation. GSVP's leadership and capital are essential to making that vision real. About Garden State Venture Partners Garden State Venture Partners (GSVP) is a next-gen venture capital firm built to attract and retain companies and talent within the state of New Jersey. GSVP is uniquely positioned to deepen existing partnerships and forge new ones across the state—catalyzing innovation and driving sustained economic success by connecting and investing in the state's innovation ecosystem. Learn more about GSVP at and access full leadership team bios here.
